Equities

Diurnal Group PLC

Diurnal Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.50
  • Today's Change-0.25 / -2.33%
  • Shares traded45.00k
  • 1 Year change-83.67%
  • Beta0.6341
Data delayed at least 20 minutes, as of Jul 01 2022 08:13 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Diurnal Group plc is a specialty pharmaceutical company. It is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. It focuses on addressing unmet clinical and patient needs in hormone replacement by developing and marketing products for the rare and orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). The Company’s products include Alkindi and Efmody. Its product Alkindi (hydrocortisone granules in capsules for opening) is a specifically designed for young children suffering from paediatric AI, and the related condition CAH. Its product Efmody (modified-release hydrocortisone) provides a drug release profile that is designed to improve disease treatment for adults with CAH, as measured by androgen (male sex hormone) control. Its pipeline includes DNL-0200, DNL-0300, DNL-0400 and DNL-0500.

  • Revenue in GBP (TTM)5.28m
  • Net income in GBP-13.34m
  • Incorporated2015
  • Employees36.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evgen Pharma PLC0.00-2.73m9.48m11.00--1.03-----0.0099-0.00990.000.03360.00----0.00-24.76-42.32-25.95-46.45-------6,869.07----0.00---100.00---2.09---47.61--
Proteome Sciences plc5.13m72.00k10.63m27.00211.76--37.292.070.00020.00020.017-0.00940.5362.214.41189,963.000.7524-7.87----57.7159.941.40-15.710.29611.401.31--7.9113.33-75.59--43.95--
Kanabo Group PLC73.00k-4.55m11.00m0.00--1.86--150.63-0.0144-0.01440.00020.0140.0228--0.3296---142.42---153.70--9.59---6,234.25--11.43--0.00-------3,374.05------
Fusion Antibodies PLC4.70m-3.01m11.97m54.00--2.81--2.55-0.1159-0.11590.18130.16380.68745.023.2687,055.55-44.04-21.34-50.93-24.7150.0347.45-64.07-36.643.57-166.880.0346--6.9322.97-315.93--59.14--
Hemogenyx Pharmaceuticals PLC0.00-5.10m12.74m10.00--1.55-----0.0081-0.00810.000.00840.00----0.00-91.34-96.46-112.36-120.13-----------1.050.0012-------144.89--34.08--
Abingdon Health PLC5.64m-12.85m13.39m151.00--0.6133--2.38-0.0949-0.09490.030.17940.15810.84210.669937,317.88-36.04---49.56---1.38---228.02--1.48-167.050.0572--121.93---106.69------
Oxford Biodynamics PLC176.00k-6.63m13.55m39.00--2.06--76.97-0.0695-0.06950.00180.06550.0133--0.18324,512.82-50.16-24.63-57.11-26.67-----3,768.18-480.922.80--0.4983---25.22-20.75-53.64--71.53--
Shield Therapeutics PLC1.95m-13.04m16.21m16.00--0.3174--8.32-0.0817-0.08170.01220.23630.0430.53481.54121,812.50-28.76-24.56-30.15-27.0361.3189.95-668.91-199.8717.86-451.480.00--1,344.65--70.11---29.49--
IXICO PLC8.20m949.00k17.09m93.0018.971.4810.832.080.01870.01870.1620.23980.6088--2.9988,161.297.041.598.192.1361.5963.7311.562.11--23.000.04510.00-3.5922.9765.44--145.81--
MiLOC Group Limited1.05m2.07m17.10m6.008.37----16.230.02380.02380.0123-0.04760.6381.754.21--98.95-111.75----23.0239.32155.09-146.300.08342.56----32.5619.76124.34--24.85--
OptiBiotix Health PLC1.85m20.68m18.05m8.000.97640.69030.86189.740.210.210.01850.2970.10458.012.21231,808.80116.555.69120.406.0357.0061.061,114.9664.923.72--0.0298--104.50122.08345.09--181.84--
Genincode PLC1.15m-4.14m18.21m20.00--1.33--15.78-0.0432-0.04320.0120.14320.130934.893.5657,700.00-46.98---51.02--51.39---358.93--18.00--0.00--20.11---255.23------
Diurnal Group PLC5.28m-13.34m18.24m36.00--0.6078--3.45-0.0839-0.08390.03350.17690.17340.51987.80146,722.20-43.79-43.08-50.20-50.3383.13---252.54-427.577.13-22.990.00---30.76---146.78------
Provexis plc479.46k-283.34k18.30m2.00--11.74--38.16-0.0001-0.00010.00020.00070.60280.55874.05239,730.00-37.93-96.20-26.38-55.1389.0189.81-62.92-133.986.32--0.00--45.2340.7016.05------
Data as of Jul 01 2022. Currency figures normalised to Diurnal Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

36.97%Per cent of shares held by top holders
HolderShares% Held
Polar Capital LLPas of 04 Nov 202118.67m11.00%
Chelverton Asset Management Ltd.as of 13 Sep 20219.75m5.75%
J.O. Hambro Capital Management Ltd.as of 06 Jan 20228.44m4.97%
BGF Investment Management Ltd.as of 13 Sep 20217.54m4.44%
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Apr 20224.21m2.48%
SVM Asset Management Ltd.as of 31 Dec 20213.30m1.94%
Oceanwood Capital Management LLPas of 20 Sep 20193.15m1.86%
Walker Crips Investment Management Ltd.as of 02 Apr 20222.68m1.58%
IG Markets Ltd.as of 02 Apr 20222.57m1.52%
Hargreaves Lansdown Asset Management Ltd.as of 02 Apr 20222.44m1.44%
More ▼
Data from 31 Dec 2021 - 17 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.